{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:00:26Z","timestamp":1790805626967,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T00:00:00Z","timestamp":1712448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2017383"],"award-info":[{"award-number":["2017383"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1182443"],"award-info":[{"award-number":["1182443"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health and Aged Care, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AI144182"],"award-info":[{"award-number":["U19 AI144182"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.vaccine.2024.03.068","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T08:25:18Z","timestamp":1711787118000},"page":"S70-S81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"S1","title":["Review of mathematical models of Neisseria gonorrhoeae vaccine impact: Implications for vaccine development"],"prefix":"10.1016","volume":"42","author":[{"given":"Thilini N.","family":"Padeniya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben B.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7094-3528","authenticated-orcid":false,"given":"Kate L.","family":"Seib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.vaccine.2024.03.068_b0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.2471\/BLT.18.228486","article-title":"Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016","volume":"97","author":"Rowley","year":"2019","journal-title":"Bull World Health Organ"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.068_b0010","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CMR.00010-14","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future","volume":"27","author":"Unemo","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2024.03.068_b0015","doi-asserted-by":"crossref","unstructured":"Day, M., et al., Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022. Euro Surveill, 2022. 27(46) DOI: doi: 10.2807\/1560-7917.ES.2022.27.46.2200803.","DOI":"10.2807\/1560-7917.ES.2022.27.46.2200803"},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.068_b0020","doi-asserted-by":"crossref","first-page":"e02294","DOI":"10.1128\/aac.02294-21","article-title":"Markedly increasing antibiotic resistance and dual treatment of Neisseria gonorrhoeae isolates in Guangdong, China, from 2013 to 2020","volume":"66","author":"Lin","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.vaccine.2024.03.068_b0025","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3201\/eid2206.152091","article-title":"Neisseria gonorrhoeae resistant to ceftriaxone and cefixime, Argentina","volume":"22","author":"Gianecini","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.068_b0030","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3201\/eid2402.171756","article-title":"Ceftriaxone-resistant Neisseria gonorrhoeae, Canada, 2017","volume":"24","author":"Lefebvre","year":"2018","journal-title":"Emerg Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2024.03.068_b0035","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea","volume":"379","author":"Taylor","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.068_b0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1258\/0956462021924712","article-title":"What proportion of episodes of gonorrhoea and chlamydia becomes symptomatic?","volume":"13","author":"Korenromp","year":"2002","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.vaccine.2024.03.068_b0045","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1017\/S0950268820002265","article-title":"Clinical presentation of asymptomatic and symptomatic women who tested positive for genital gonorrhoea at a sexual health service in Melbourne, Australia","volume":"148","author":"Mart\u00edn-S\u00e1nchez","year":"2020","journal-title":"Epidemiol Infection"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.068_b0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1086\/430704","article-title":"Prevalence of rectal, urethral, and Pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003","volume":"41","author":"Kent","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.068_b0055","unstructured":"World Health Organization. WHO preferred product characteristics for gonococcal vaccines. 2021."},{"issue":"8","key":"10.1016\/j.vaccine.2024.03.068_b0060","first-page":"252","article-title":"Recommendations for the diagnosis of Neisseria gonorrhoeae and chlamydia trachomatis, including extra-genital sites","volume":"95","author":"Chan","year":"2012","journal-title":"Med Health R I"},{"key":"10.1016\/j.vaccine.2024.03.068_b0065","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0140-6736(98)90002-2","article-title":"Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis","volume":"351","author":"Cohen","year":"1998","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2024.03.068_b0070","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/cid\/cit437","article-title":"HIV incidence among men with and those without sexually transmitted rectal infections: estimates from matching against an HIV case registry","volume":"57","author":"Pathela","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.068_b0075","unstructured":"World Health Organization (WHO). Global Health Sector Strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. 2022."},{"issue":"28","key":"10.1016\/j.vaccine.2024.03.068_b0080","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1016\/j.vaccine.2020.02.073","article-title":"Gonococcal vaccines: public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019","volume":"38","author":"Gottlieb","year":"2020","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.068_b0085","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/QCO.0000000000000450","article-title":"Neisseria gonorrhoeae vaccine development: hope on the horizon?","volume":"31","author":"Edwards","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.068_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.03.068_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00754-4","article-title":"Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study","author":"Wang","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.068_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00812-4","article-title":"Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study","author":"Abara","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.068_b0105","article-title":"Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in Southern California","author":"Bruxvoort","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.068_b0110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jinf.2023.05.021","article-title":"4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation","volume":"87","author":"Wang","year":"2023","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2024.03.068_b0115","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3109\/1040841X.2015.1105782","article-title":"Is gonococcal disease preventable? the importance of understanding immunity and pathogenesis in vaccine development","volume":"42","author":"Edwards","year":"2016","journal-title":"Crit Rev Microbiol"},{"issue":"26","key":"10.1016\/j.vaccine.2024.03.068_b0120","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.vaccine.2016.03.111","article-title":"The global roadmap for advancing development of vaccines against sexually transmitted infections: update and next steps","volume":"34","author":"Gottlieb","year":"2016","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.068_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-022-14670-z","article-title":"The potential public health impact of adolescent 4CMenB vaccination on Neisseria gonorrhoeae infection in England: a modelling study","volume":"23","author":"Looker","year":"2023","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2024.03.068_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2022.10.031","article-title":"Estimating the population level impact of a gonococcal vaccine candidate: predictions from a simple mathematical model","author":"Carey","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.068_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2023.07.048","article-title":"The potential impact of a vaccine on Neisseria gonorrhoeae prevalence among heterosexuals living in a high prevalence setting","author":"Padeniya","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.068_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00744-1","article-title":"Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis","author":"Whittles","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.068_b0145","article-title":"The impact of vaccination on Neisseria gonorrhoeae antimicrobial resistance and prevalence in men who have sex with men: a mathematical modelling study","author":"Heijne","year":"2020","journal-title":"medRxiv"},{"issue":"8","key":"10.1016\/j.vaccine.2024.03.068_b0150","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/cid\/ciz1241","article-title":"Assessment of the potential of vaccination to combat antibiotic resistance in gonorrhea: a modeling analysis to determine preferred product characteristics","volume":"71","author":"Whittles","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"36","key":"10.1016\/j.vaccine.2024.03.068_b0155","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1016\/j.vaccine.2015.07.015","article-title":"The potential impact of vaccination on the prevalence of gonorrhea","volume":"33","author":"Craig","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.068_b0160","article-title":"A gonococcal vaccine has the potential to rapidly reduce the incidence of Neisseria gonorrhoeae infection among urban men who have sex with men","author":"Hui","year":"2021","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.068_b0165","doi-asserted-by":"crossref","first-page":"e1006748","DOI":"10.1371\/journal.pcbi.1006748","article-title":"A dynamic power-law sexual network model of gonorrhoea outbreaks","volume":"15","author":"Whittles","year":"2019","journal-title":"PLoS Comput Biol"},{"issue":"5","key":"10.1016\/j.vaccine.2024.03.068_b0170","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1071\/SH19061","article-title":"Epidemiology of gonorrhoea: a global perspective","volume":"16","author":"Kirkcaldy","year":"2019","journal-title":"Sex Health"},{"issue":"6","key":"10.1016\/j.vaccine.2024.03.068_b0175","first-page":"422","article-title":"Gonorrhoea in men: clinical and diagnostic aspects","volume":"72","author":"Sherrard","year":"1996","journal-title":"Genitourin Med"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.068_b0180","first-page":"184","article-title":"Some factors affecting the incubation period and duration of symptoms of urethritis in men","volume":"58","author":"Schofield","year":"1982","journal-title":"Br J Vener Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2024.03.068_b0185","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00007435-200110000-00001","article-title":"Experimental gonococcal urethritis and reinfection with homologous gonococci in male volunteers","volume":"28","author":"Schmidt","year":"2001","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2024.03.068_b0190","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.3389\/fimmu.2018.03187","article-title":"Human immune responses and the natural history of Neisseria gonorrhoeae infection","volume":"9","author":"Lovett","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.068_b0195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00007435-199201000-00009","article-title":"The contribution of reinfection to gonorrhea incidence in Alaska, 1983 to 1987","volume":"19","author":"Beller","year":"1992","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2024.03.068_b0200","first-page":"1604","article-title":"Gonorrhoea","volume":"2014","author":"Creighton","year":"2014","journal-title":"BMJ Clinical Evidence"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.068_b0205","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/sti.2009.037341","article-title":"A bayesian approach to uncertainty analysis of sexually transmitted infection models","volume":"86","author":"Johnson","year":"2010","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2024.03.068_b0210","unstructured":"World Health Organization. Prevalence and incidence: Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis. Methods and results used by WHO to generate 2005 estimates. 2011."},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.068_b0215","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/sextrans-2015-052214","article-title":"An estimate of the proportion of symptomatic gonococcal, chlamydial and non-gonococcal non-chlamydial urethritis attributable to oral sex among men who have sex with men: a case\u2013control study","volume":"92","author":"Barbee","year":"2016","journal-title":"Sex Transm Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.068_b0220","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/sextrans-2012-050929","article-title":"Prevalence of pharyngeal and rectal chlamydia trachomatis and Neisseria gonorrhoeae infections among men who have sex with men in Germany","volume":"90","author":"Dudareva-Vizule","year":"2014","journal-title":"Sex Transm Infect"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.068_b0225","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1086\/598983","article-title":"Modeling the impact of potential vaccines on epidemics of sexually transmitted chlamydia trachomatis infection","volume":"199","author":"Gray","year":"2009","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2024.03.068_b0230","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1071\/SH19023","article-title":"World Health Organization global gonococcal antimicrobial surveillance program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts","volume":"16","author":"Unemo","year":"2019","journal-title":"Sex Health"},{"issue":"Supplement_1","key":"10.1016\/j.vaccine.2024.03.068_b0235","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/clinids\/20.Supplement_1.S47","article-title":"Drugs of choice for the treatment of uncomplicated gonococcal infections","volume":"20","author":"Moran","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2024.03.068_b0240","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1086\/648428","article-title":"Pharyngeal gonorrhea: an important reservoir of infection?","volume":"49","author":"Weinstock","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2024.03.068_b0245","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/OLQ.0000000000000661","article-title":"Neisseria gonorrhoeae transmission among men who have sex with men: an anatomical site-specific mathematical model evaluating the potential preventive impact of mouthwash","volume":"44","author":"Zhang","year":"2017","journal-title":"Sex Transm Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.068_b0250","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/sti.2009.036814","article-title":"Prevalence, incidence and risk factors for pharyngeal gonorrhoea in a community-based HIV-negative cohort of homosexual men in Sydney","volume":"86","author":"Templeton","year":"2010","journal-title":"Australia Sexually Transmitted Infections"},{"issue":"11","key":"10.1016\/j.vaccine.2024.03.068_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11111230","article-title":"Current susceptibility surveillance and distribution of antimicrobial resistance in N. gonorrheae within WHO regions","volume":"11","author":"Radovanovic","year":"2022","journal-title":"Pathogens"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.068_b0265","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","article-title":"Gonorrhoea","volume":"5","author":"Unemo","year":"2019","journal-title":"Nat Rev Disease Primers"},{"issue":"2","key":"10.1016\/j.vaccine.2024.03.068_b0270","doi-asserted-by":"crossref","first-page":"E74","DOI":"10.1503\/cmaj.140900","article-title":"Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario grade 8 HPV vaccine cohort study","volume":"187","author":"Smith","year":"2015","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.068_b0275","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amepre.2011.09.024","article-title":"Human papillomavirus vaccine and sexual behavior among adolescent and young women","volume":"42","author":"Liddon","year":"2012","journal-title":"Am J Prev Med"},{"issue":"4","key":"10.1016\/j.vaccine.2024.03.068_b0280","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/jamainternmed.2014.7886","article-title":"Incidence of sexually transmitted infections after human papillomavirus vaccination among adolescent females","volume":"175","author":"Jena","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.vaccine.2024.03.068_b0285","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1471-2458-14-155","article-title":"No difference in sexual behavior of adolescent girls following human papilloma virus vaccination: a case study two districts in Uganda, Nakasongola and Luwero","volume":"14","author":"Aujo","year":"2014","journal-title":"BMC Public Health"},{"issue":"12","key":"10.1016\/j.vaccine.2024.03.068_b0290","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1128\/JCM.05341-11","article-title":"Differing Neisseria gonorrhoeae bacterial loads in the pharynx and rectum in men who have sex with men: implications for gonococcal detection, transmission, and control","volume":"49","author":"Bissessor","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2024.03.068_b0295","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/infdis\/169.3.532","article-title":"Human Experimentation with Neisseria gonorrhoeae: rationale, methods, and implications for the biology of infection and vaccine development","volume":"169","author":"Cohen","year":"1994","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2024.03.068_b0300","doi-asserted-by":"crossref","DOI":"10.1097\/OLQ.0b013e31820ff9a4","article-title":"The natural history of incident gonococcal infection in adolescent women","volume":"38","author":"Stupiansky","year":"2011","journal-title":"Sex Transm Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.068_b0305","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1186\/s12889-023-15516-y","article-title":"An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol","volume":"23","author":"Thng","year":"2023","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.068_b0310","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1172\/JCI116190","article-title":"Antibody to rmp (outer membrane protein 3) increases susceptibility to gonococcal infection","volume":"91","author":"Plummer","year":"1993","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.vaccine.2024.03.068_b0315","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1471-2334-13-188","article-title":"Population movement can sustain STI prevalence in remote australian indigenous communities","volume":"13","author":"Hui","year":"2013","journal-title":"BMC Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:33:04Z","timestamp":1778679184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24003803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":62,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0264410X24003803"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.068","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of mathematical models of Neisseria gonorrhoeae vaccine impact: Implications for vaccine development","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}